In case of sale, Cempra execs primed for golden parachutes

Chapel Hill-based Cempra (Nasdaq: CEMP) – which has struggled to regain footing after the U.S. Food and Drug Administration did not approved its pneumonia drug solithromycin in December of last year – has disclosed in an SEC filing that, should a sale of the company ensue, its acting CEO and other C-suite executives are primed for gol den parachutes. According to the filing, the company has entered into a change in control severance agreement with acting CEO Dr. David Zaccardelli and into an…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news